These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36120536)

  • 21. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
    Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.
    Zhang W; Kong Y; Li Y; Shi F; Lyu J; Sheng C; Wang S; Wang Q
    Front Immunol; 2021; 12():798474. PubMed ID: 35087523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
    Lamba N; Ott PA; Iorgulescu JB
    JAMA Netw Open; 2022 Aug; 5(8):e2225459. PubMed ID: 36006646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.
    Long J; Wang D; Yang X; Wang A; Lin Y; Zheng M; Zhang H; Sang X; Wang H; Hu K; Zhao H
    BMC Med; 2021 Jul; 19(1):154. PubMed ID: 34284787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer.
    Sun L; Li M; Deng L; Niu Y; Tang Y; Wang Y; Guo L
    Front Pharmacol; 2021; 12():625593. PubMed ID: 33927616
    [No Abstract]   [Full Text] [Related]  

  • 26. Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohort.
    Li Y; Chen Z; Wu L; Tao W
    Ann Transl Med; 2020 Apr; 8(7):446. PubMed ID: 32395490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of
    Wang X; Wu B; Yan Z; Wang G; Chen S; Zeng J; Tao F; Xu B; Ke H; Li M
    Front Oncol; 2021; 11():650122. PubMed ID: 34123798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma.
    Li H; Zhang Q; Duan Q; Tan Y; Sun T; Qi C
    Front Immunol; 2022; 13():894110. PubMed ID: 35967450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.
    Lodde GC; Jansen P; Möller I; Sucker A; Hassel JC; Forschner A; Eckardt J; Meier F; Reinhardt L; Kähler KC; Ziemer M; Schlaak M; Rahimi F; Schatton K; Meiss F; Gutzmer R; Pföhler C; Terheyden P; Schilling B; Sachse M; Heppt MV; Sindrilaru A; Leiter U; Zaremba A; Thielmann CM; Ugurel S; Zimmer L; Hadaschik E; Bechrakis NE; Schadendorf D; Westekemper H; Livingstone E; Griewank KG;
    Eur J Cancer; 2022 May; 166():60-72. PubMed ID: 35279471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CARD11 alteration as a candidate biomarker of skin cutaneous melanoma treated with immune checkpoint blockade.
    Si Y; Lin A; Ding W; Meng H; Luo P; Zhang J
    Am J Transl Res; 2021; 13(1):286-300. PubMed ID: 33527024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.
    Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
    J Am Acad Dermatol; 2023 May; 88(5):1024-1032. PubMed ID: 36736626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma.
    Bol KF; Ellebaek E; Hoejberg L; Bagger MM; Larsen MS; Klausen TW; Køhler UH; Schmidt H; Bastholt L; Kiilgaard JF; Donia M; Svane IM
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pathway-based mutation signature to predict the clinical outcomes and response to CTLA-4 inhibitors in melanoma.
    Wang Q; Li X; Qiu J; He Y; Wu J; Li J; Liu W; Han J
    Comput Struct Biotechnol J; 2023; 21():2536-2546. PubMed ID: 37102155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers.
    Yang X; Hu Y; Yang K; Wang D; Lin J; Long J; Xie F; Mao J; Bian J; Guan M; Pan J; Huo L; Hu K; Yang X; Mao Y; Sang X; Zhang J; Wang X; Zhang H; Zhao H
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Immune-Related Gene Pair Index Predicts Clinical Response and Survival Outcome of Immune Checkpoint Inhibitors in Melanoma.
    Yan J; Wu X; Yu J; Kong Y; Cang S
    Front Immunol; 2022; 13():839901. PubMed ID: 35280982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry.
    Jacob A; Wu J; Kolesar J; Durbin E; Mathew A; Arnold S; Chauhan A
    Cancer Med; 2021 Mar; 10(6):2054-2062. PubMed ID: 33619913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Ranganath H; Jain AL; Smith JR; Ryder J; Chaudry A; Miller E; Hare F; Valasareddy P; Seitz RS; Hout DR; Varga MG; Schweitzer BL; Nielsen TJ; Mullins J; Ross DT; Gandara DR; Vidal GA
    BMC Cancer; 2022 Apr; 22(1):407. PubMed ID: 35421940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
    Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
    ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
    Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.